Background. Patients with diabetes mellitus (DM) with chronic kidney disease (CKD) often have no proteinuria. Methods. To compare the characteristics that differ between DM 1 CKD patients with and without proteinuria, we conducted a cross-sectional study followed by surveillance over a decade for 'hard' cardiovascular, renal and retinal outcomes. Groups were stratified by presence (n ¼ 129) and absence (n ¼ 284) of DM. Each stratum had three groups: no CKD, CKD without proteinuria and CKD with proteinuria.
Introduction
Diabetic nephropathy is the leading cause of both end-stage renal disease (ESRD) and cardiovascular disease in the developed economies [1] . At its earliest stage, diabetic nephropathy is clinically recognized by persistent albuminuria [2] . When the extent of albuminuria is between 30 and 300 mg/g creatinine (referred to as microalbuminuria), glomerular filtration rate (GFR) is often preserved [estimated GFR (eGFR) >60 mL/min/1.73m 2 ] [1] . Typically, microalbuminuria progresses to macroalbuminuria and this is followed by reduction in GFR [2] . However, a number of patients who have type 2 diabetes mellitus (DM) present to their nephrologist with an impaired GFR, yet little or no albuminuria [3] . Kidney biopsies are rarely performed in such patients, but in the absence of other obvious causes of kidney disease, these patients are often thought to have diabetic nephropathy [4] . Both the characteristics of these patients and the natural course of their disease are poorly understood [5] .
Over the last decade, we have studied a group of veterans, predominantly older men, who have CKD from a variety of causes [6, 7] . At inception of this cohort, we measured blood pressure (BP) (in clinic and at home) and collected demographic and clinical information about their kidney disease and cardiovascular disease. During follow-up, while these patients continued to receive care from their physicians mostly within the Veterans Administration hospitals, we recorded 'hard' cardiovascular and renal events.
Among patients with diabetes and CKD, the purpose of this report was to compare the clinical characteristics of those with no (or minimal) proteinuria to those with overt proteinuria. Over a follow-up period of a decade, we then compared the two groups with respect to incident retinopathy, incident ESRD, cardiovascular events and death. As a control group, we studied patients with DM but without CKD at baseline. Furthermore, we compared the group of interest to three other groups of patients (controls, CKD with minimal proteinuria and CKD with overt proteinuria) who did not have diabetes.
Methods
The cohort was assembled prospectively from the renal and a general medical clinic at the Roudebush VA Medical Center, Indianapolis, between 17 October 2000 and 29 May 2002 and has been previously described [6] . Consecutive patients were enrolled if they were !18 years of age. Patients were excluded for body mass index >40 kg/m 2 ; acute renal failure; receiving renal replacement therapy; atrial fibrillation or change in their antihypertensive regimens within 2 weeks of study enrollment.
DM was defined as need for medications, either oral hypoglycemic agents or insulin at the time of consent. For the purpose of this report, CKD was defined as eGFR of <60 mL/min/1.73m 2 or spot urine protein/ creatinine ratio of >0.22 g/g which represents >300 mg protein excretion rate per day and therefore represents overt proteinuria. ESRD was defined as the point in time when dialysis was initiated. ESRD was also noted to be present when it was indicated but the patient refused dialysis. When the patient was not seen for >6 months in the VA system, the social security death index was searched to ascertain mortality. Medical records of each patient were then reviewed for the ascertainment of any of the following events: stroke, myocardial infarction and coronary revascularization (either by surgery or percutaneously). The presence of diabetic retinopathy was determined among patients with DM by chart review. The etiology of kidney disease was determined in each individual with CKD by chart review. Information on kidney biopsy was sought where available. Among patients who had minimal proteinuria, we ascertained the incidence of overt proteinuria. Overt proteinuria was defined as a doubling of baseline level of proteinuria together with a protein/creatinine ratio on a spot specimen of >0.22 g/g. At least two of three urine protein/creatinine results following incident event were required to meet this definition to be called positive.
The Institutional Review Board of Indiana University and the Research and Development Committee of the Richard L. Roudebush Veterans Affairs Medical Center approved this study, and all patients gave their written and informed consent.
Statistical analysis
Cross-sectional analysis. Means between groups were analyzed with one-way analysis of variance. Proportions were compared with the chisquared test. Linear regression with indicator variables was used to compare the effect of diabetes, CKD, proteinuria and their interactions on outcome variables. P-values reported are unadjusted for multiple comparisons.
Longitudinal follow-up
Five outcomes of interest were the following: death, myocardial infarction or coronary revascularization, stroke, ESRD or a combination of first time of these events. Indicator variables were used for diabetes (two levels), CKD and its severity (three levels: no CKD, CKD with low proteinuria and CKD with overt proteinuria) and their interaction in a Cox model. Patients without diabetes and CKD were used as the reference category. Linear trends for increasing severity of proteinuria within diabetes group and within nondiabetic group were tested using orthogonal contrast coefficients. The independent effects of DM, CKD and the interaction of diabetes with CKD and its severity were tested using the Wald test. Schoenfeld residuals were tested to assess the proportionality assumption in the model. Firstly, unadjusted hazard ratios (HRs) were calculated. Then, we calculated multivariate adjusted HRs using the following variables: age, sex, race, seated clinic systolic BP, prevalent cardiovascular disease, ACE inhibitor or ARB use, statin use, aspirin use, antihypertensive drug use and current smoking.
Results
There were 35 diabetics without CKD, 25 diabetics with CKD but without overt proteinuria and 69 diabetics with CKD and overt proteinuria. Cross-sectional comparisons among the three groups are shown in Table 1 . Compared to controls, patients with CKD (combined group of with or without proteinuria) differed in the following characteristics. They were older, more often current smokers, had greater antihypertensive medication use, took a greater number of antihypertensive medications, took less thiazides, more loop diuretics, more dihydropyridines and took twice as many statins. However, they had a higher BP and lower hemoglobin. Compared to patients with CKD without proteinuria, those with proteinuria had higher clinic and ambulatory BP. However, the two groups were similar with respect to eGFR, hemoglobin, antihypertensive drug use or the number of antihypertensive drugs used to control BP. Table 2 shows the clinical characteristics of a control group without DM. There were 158 controls (veterans attending a general medicine clinic) without CKD, 68 nondiabetics with CKD but without overt proteinuria and 58 nondiabetics with CKD and overt proteinuria. Compared to controls, patients with CKD (combined group of with or without proteinuria) differed in the following characteristics: they were older, less often current smokers, had more coronary artery disease, greater antihypertensive medication use, took a greater number of antihypertensive medications that included more loop diuretics, dihydropyridines, alpha blockers, beta blockers, vasodilators, ACE inhibitors and ARBs; they also took more statins and asprin. Compared to patients with CKD without proteinuria, those with proteinuria had higher clinic and ambulatory BP. However, the two groups were similar with respect to eGFR, hemoglobin, antihypertensive drug use or the number of antihypertensive drugs used to control BP.
Among patients with diabetes but no proteinuria, the distribution of kidney disease etiologies as ascertained clinically were as follows: diabetes 52%, hypertension 32%, ischemic 8%, analgesic nephropathy 4% and heart failure 4%. The distribution among those with proteinuria was as follows: diabetes 62%, hypertension 23%, ischemic 7%, polycystic kidney disease 1% and glomerulonephritis 5%. Kidney biopsies were performed in nine patients; all were in the proteinuric group. The etiologies were hypertensive nephrosclerosis (two), diabetic nephropathy (three) and glomerulonephritis (four). Of the four patients with glomerulonephritis, the etiologies were focal segmental glomerulosclerosis, fibrillary glomerulonephritis, membranous glomerulonephritis and chronic glomerulonephritis. One additional patient in the control group had a kidney biopsy after developing proteinuria and renal impairment. Early diabetic nephropathy was diagnosed. Among the 86 patients with DM and CKD who had an ultrasound, the right kidney measured 11.7 cm and the left kidney 11.9 cm. No differences were present in kidney size between groups. Diabetic CKD with no proteinuriahemoglobin A1C measurements were available in 63% of the controls, 48% of those with no proteinuria and 42% of those with proteinuria. They averaged 8.0 AE 2.7, 7.9 AE 1.5 and 7.2 AE 1.5%, respectively (P ¼ NS).
Retinal examinations were available in 33 of 34 patients (97%) with no CKD, 21 of 25 (84%) of those with no proteinuria and 48 of 69 (70%) of those with proteinuria. At baseline, 1 of 33 (3%) with no CKD, 7 of 21 patients (33%) with CKD but no proteinuria and 10 of 48 (21%) patients with CKD 1 proteinuria had retinopathy (P ¼ 0.011). Over the follow-up, a few patients developed retinopathy: 11 (33%) in the no CKD group, 4 (29%) patients in the CKD but no proteinuria group and 24 (63%) in the proteinuria group (P ¼ 0.015). The cumulative hazard for developing retinopathy by groups is shown in Figure 1 . Compared to the CKD group without proteinuria, the CKD group with proteinuria was more likely to develop retinopathy (P ¼ 0.026).
The long-term outcomes of interest are shown in Table 3 . The average follow-up of the cohort was 6.8 years. Loss to follow-up was defined as time of last ascertainment, at least a 12 months absence of being evaluated in the VA system. Using this definition, of the 212 patients who did not die or experience ESRD, only 16 were lost to follow-up. Crude all-cause mortality rates in the nondiabetic group with no CKD, CKD with no proteinuria and CKD with overt proteinuria were 29.3 per 1000 patient-years, 68.5 per 1000 patient-years and 111.1 per 1000 patient-years, respectively. Compared to the reference group of nondiabetics with no CKD, the adjusted HR for CKD without proteinuria was 1.58 and CKD with proteinuria was 2.87 (P < 0.0001 for trend). Crude all-cause mortality rates in the diabetic group with no CKD, CKD with no proteinuria and CKD with overt proteinuria were 50.1 per 1000 patient-years, 105.7 per 1000 patient-years and 136.8 per 1000 patient-years, respectively. Compared to the reference group of nondiabetics with no CKD, the adjusted HR for diabetic with CKD, diabetic CKD without proteinuria and diabetic CKD with proteinuria was 1.58, 2.83 and 3.29, respectively (P < 0.0001 for trend). Although both proteinuria and CKD were associated with increased risk for allcause mortality, diabetes did not compound the risk of proteinuria on mortality (P ¼ 0.5). Similarly, a 'doseresponse' relationship between increasing severity of CKD and either ESRD or composite event was seen. This was true for those with diabetes and those without diabetes. However, such a dose-response relationship between increasing severity of CKD and either coronary events or strokes was evident only among diabetics. Diabetes did not compound the risk of proteinuria on mortality for any end point studied (Figure 2 ).
Systolic clinic BP was an independent determinant of the following outcomes: ESRD (HR 1.029 per mmHg, P < 0.001), coronary events (HR 1.018, P ¼ 0.007) and composite event (HR 1.009, P ¼ 0.01). However, systolic clinic BP was not an independent determinant of death (HR 1.007, P ¼ 0.081) or stroke (HR 0.997, P ¼ 0.77) outcome.
Nondiabetics with CKD but no proteinuria at baseline developed overt proteinuria in 12 cases of 68 with a rate of 28.9 per 1000 patient-years. In contrast, diabetics with CKD but no proteinuria at baseline developed overt proteinuria in 10 cases of 25 with a rate of 102.8 per 1000 patient-years. The unadjusted HR for the development of overt proteinuria was 3.28 [95% confidence interval (CI) 1.40-7.67], P < 0.01. Adjustments for the following variables: age, sex, race, clinic systolic BP, ACE/ARB use, statin use, aspirin use, antihypertensive use, smoking history and past history of coronary events increased the HR to 5.28 (95% CI 1.64-17.02), P < 0.01.
Discussion
Pathologically, diabetic nephropathy is now recognized as a continuum of glomerular lesions of increasing severity that fall into four hierarchical classes as follows [8] . Class I: isolated glomerular basement membrane thickening; Class II: mesangial expansion; Class III: glomerulosclerosis either nodular (Kimmelstiel-Wilson lesion) or global and Class IV: advanced diabetic glomerulosclerosis. The last stage is characterized by >50% global glomerulosclerosis with other clinical or pathologic evidence that sclerosis is attributable to diabetic nephropathy. The degree of interstitial and vascular involvement is independently evaluated in each class. Some clinical-pathological correlates have been observed. For example, urine albumin excretion rate correlates strongly with basement membrane thickness and mesangial expansion [9] . In contrast, the Kimmelstiel-Wilson lesion heralds on the onset of more severe diabetic nephropathy [8] . Both the Kimmelstiel-Wilson lesion and Class IV diabetic nephropathy are associated more closely with an impaired GFR. Most importantly, the degree of interstitial fibrosis and tubular atrophy as well as the extent of arteriolar hyalinosis are associated with impairment in GFR [8, 10] . Thus, we hypothesized that impaired GFR with no overt proteinuria may herald more advanced interstitial and vascular disease. If so, then impaired GFR with no overt proteinuria may share clinical characteristics and a clinical course that is different from those with overt proteinuria.
In cross-sectional analyses, we discovered that patients with diabetic CKD and no proteinuria had one important difference from their more proteinuric counterparts. Despite receiving a similar number of antihypertensive drugs, these nonproteinuric patients had 20/7 mmHg lower clinic BP and 15/5 mmHg lower 24-h ambulatory BP. This lower b Coronary events are defined as any myocardial infarction, percutaneous transluminal coronary angioplasty or coronary artery bypass graft. *0.01 < P < 0.05, **0.001 < P < 0.01 and ***0.0001 < P < 0.001.
Diabetic CKD with no proteinuria BP among nonproteinuric patients cannot be attributed to a better eGFR; the two groups had similarly low eGFR. Thus, proteinuria per se was a marker of hypertension, but not through a more impaired GFR. Proteinuria is now shown to be strongly and independently associated with poor control of hypertension in population-based studies [11, 12] . A number of possibilities may explain the relationship between proteinuria and hypertension. Higher BP may be seen in those with proteinuria due to greater arterial stiffness, sodium retention, sympathetic activation or increased circulating asymmetric dimethyl arginine.
No other clinical differences emerged between diabetic groups with CKD with and without proteinuria. For example, the distribution of diabetic and nondiabetic etiologies of CKD was similar between those with no proteinuria and those with overt proteinuria. We found a few patients with glomerulonephritis among those with overt proteinuria. Among 36 patients enrolled in a prospective clinical trial of patients with type 2 DM, proteinuria, renal failure and hypertension, Schwartz et al. [13] reported two patients (6%) who had glomerulonephritis . This prevalence was similar to what we found (5%). A review of biopsy studies among patients with diabetes revealed that the prevalence of nondiabetic kidney disease varied from 12 to 81% [4] . However, when electron microscopy was available, the prevalence of nondiabetic kidney disease dropped to 9-18% [4] . Kidney sonograms, performed in a large percent of patients (>85%), did not reveal differences in kidney size in relationship to proteinuria. About half the patients had information on glycemic control; the degree of glycemic control was similar. Thus, clinical markers did not distinguish between proteinuric groups with diabetic CKD. However, retinopathy was an exception.
A large number of patients had available retinal examinations. The prevalence of diabetic retinopathy was higher in the group with CKD but was similar between proteinuric and nonproteinuric groups. However, incident retinopathy appeared to develop more often when more proteinuria was present. These data are consistent with the Wisconsin Epidemiologic Study of Diabetic Retinopathy [14] . Over 14 years of follow-up, in contrast to 34.6% of those without proteinuria, progression to proliferative diabetic retinopathy was seen among 57.4% of those with proteinuria (P < 0.001) [14] . The incidence of macular edema was 24.2% among those without proteinuria but 42.1% among those with proteinuria (P < 0.001) [14] . The Wisconsin Epidemiologic Study of Diabetic Retinopathy was limited to type 1 diabetics and was done in an era when statin and ACE inhibitor use was not widespread. The cumulative hazard of 0.5 by 2 years, despite widespread use of statins and ACE inhibitors/angiotensin receptor blockers, among patients largely with type 2 diabetes indicates that greater vigilance with respect to eye examinations is required among diabetic patients with CKD and proteinuria.
It is now well recognized that in the general population eGFR is a powerful predictor of all-cause mortality and both cardiovascular morbidity and mortality [15, 16] . Low eGFR is also a cardiovascular and mortality risk factor among diabetics [17] . It has also been known for at least a decade that proteinuria among diabetic patients increases cardiovascular risk [18] . In the United Kingdom Prospective Diabetes Study, proteinuria was found to be a strong marker of death, development of renal failure and cardiovascular disease [19] . More recent randomized trials have confirmed that patients with diabetic nephropathy have increased renal and cardiovascular morbidity and mortality when they are more proteinuric [20] [21] [22] [23] . However, these Among nondiabetics, increasing risk for death was seen with CKD with increasing severity of proteinuria. This risk was higher among diabetics, but the relative risk for death with increasing severity of proteinuria was no more increased among diabetics compared to nondiabetics. A pattern similar to that seen for death was seen for the time to first of any of the following events: ESRD, coronary event, stroke or death. These are shown as composite event in the right panel. The HRs shown are multivariate adjusted (as described in statistical methods).
randomized trials or cohort studies did not have a nondiabetic control group so they were unable to evaluate the relative risk of proteinuria in the diabetic population compared to the relative risk in the nondiabetic population.
In longitudinal analyses, we discovered that patients with diabetic CKD and no proteinuria, despite having a similar eGFR as those with overt proteinuria, had lower cardiovascular, ESRD or death risk. This was in line with previous post-hoc analyses of randomized trials [20] [21] [22] [23] . However, the novel finding in our study was that the hazard of hard outcomes among diabetics with CKD with proteinuria relative to those with no proteinuria was increased to a degree similar to that seen among nondiabetics. Although diabetes did not confound the relationship of proteinuria with outcomes among those with CKD, diabetes was more likely to lead to incident overt proteinuria over the long-term. Thus, we speculate that diabetes may accelerate the cardiovascular risk of proteinuria over the lifetime of the patient.
The foremost limitation of our study is that we did not perform kidney biopsies universally among patients with diabetes and CKD. Therefore, we are uncertain whether the natural history that we describe in this report represents that of diabetic nephropathy. Many nephrologists do not biopsy such patients so our report reflects general practice. Nonetheless, our report appears to describe the long-term natural history of patients with DM with CKD with and without proteinuria. Another limitation is that we had few women. So the findings of our study are applicable to mostly men. However, it should be noted that diabetes elevates the risk of cardiovascular disease similarly among men and women [24] .
In conclusion, patients with DM with CKD but no overt proteinuria have clinical characteristics that are largely similar to those with overt proteinuria. However, thesepatients, like their nondiabetic counterparts, have lower BP and a lower cardiovascular and renal risk. In contrast to their nondiabetic counterparts, diabetic patients with CKD but no overt proteinuria are much more likely to progress to overt proteinuria. Thus, from a clinical perspective, compared to nondiabetic patients with CKD and no proteinuria, diabetic CKD patients with no proteinuria require a closer follow-up and risk factor management. Diabetic CKD is a risk factor for diabetic retinopathy. However, proteinuria is a risk factor for incident retinopathy. To protect sight, those with proteinuria and diabetic CKD need regular retinal surveillance.
